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A B S T R A C T
Background
The optimal rhythm management strategy for people with non-paroxysmal (persistent or long-standing persistent) atrial fibrilation is
currently not well defined. Antiarrhythmic drugs have been the mainstay of therapy. But recently, in people who have not responded
to antiarrhythmic drugs, the use of ablation (catheter and surgical) has emerged as an alternative to maintain sinus rhythm to avoid
long-term atrial fibrillation complications. However, evidence from randomised trials about the efficacy and safety of ablation in non-
paroxysmal atrial fibrillation is limited.
Objectives
To determine the efficacy and safety of ablation (catheter and surgical) in people with non-paroxysmal (persistent or long-standing
persistent) atrial fibrillation compared to antiarrhythmic drugs.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE Ovid, Embase Ovid, conference abstracts,
clinical trial registries, and Health Technology Assessment Database. We searched these databases from their inception to 1 April 2016.
We used no language restrictions.
Selection criteria
We included randomised trials evaluating the effect of radiofrequency catheter ablation (RFCA) or surgical ablation compared with
antiarrhythmic drugs in adults with non-paroxysmal atrial fibrillation, regardless of any concomitant underlying heart disease, with at
least 12 months of follow-up.
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Data collection and analysis
Two review authors independently selected studies and extracted data. We evaluated risk of bias using the Cochrane ’Risk of bias’ tool.
We calculated risk ratios (RRs) for dichotomous data with 95% confidence intervals (CIs) a using fixed-effect model when heterogeneity
was low (I² <= 40%) and a random-effects model when heterogeneity was moderate or substantial (I² > 40%). Using the GRADE
approach, we evaluated the quality of the evidence and used the GRADE profiler (GRADEpro) to import data from Review Manager
5 to create ’Summary of findings’ tables.
Main results
We included three randomised trials with 261 participants (mean age: 60 years) comparing RFCA (159 participants) to antiarrhythmic
drugs (102) for non-paroxysmal atrial fibrillation. We generally assessed the included studies as having low or unclear risk of bias
across multiple domains, with reported outcomes generally lacking precision due to low event rates. Evidence showed that RFCA
was superior to antiarrhythmic drugs in achieving freedom from atrial arrhythmias (RR 1.84, 95% CI 1.17 to 2.88; 3 studies, 261
participants; low-quality evidence), reducing the need for cardioversion (RR 0.62, 95% CI 0.47 to 0.82; 3 studies, 261 participants;
moderate-quality evidence), and reducing cardiac-related hospitalisation (RR 0.27, 95% CI 0.10 to 0.72; 2 studies, 216 participants;
low-quality evidence) at 12 months follow-up. There was substantial uncertainty surrounding the effect of RFCA regarding significant
bradycardia (or need for a pacemaker) (RR 0.20, 95%CI 0.02 to 1.63; 3 studies, 261 participants; low-quality evidence), periprocedural
complications, and other safety outcomes (RR 0.94, 95% CI 0.16 to 5.68; 3 studies, 261 participants; very low-quality evidence).
Authors’ conclusions
In people with non-paroxysmal atrial fibrillation, evidence suggests a superiority of RFCA to antiarrhythmic drugs in achieving freedom
from atrial arrhythmias, reducing the need for cardioversion, and reducing cardiac-related hospitalisations. There was uncertainty
surrounding the effect of RFCA with significant bradycardia (or need for a pacemaker), periprocedural complications, and other safety
outcomes. Evidence should be interpreted with caution, as event rates were low and quality of evidence ranged from moderate to very
low.
P L A I N L A N G U A G E S U M M A R Y
Benefits and harms of ablation for people with non-paroxysmal atrial fibrillation
Background
Atrial fibrillation is a heart condition that causes an irregular and often abnormally fast heart rate (tachycardia). A normal heart rate
should be regular and between 60 and 100 beats a minute when resting. In atrial fibrillation, the heart rate is irregular and can sometimes
be very fast. In some cases, it can be considerably higher than 100 beats a minute. This can cause symptoms such as dizziness, shortness
of breath, and tiredness that affect quality of life, but more importantly, atrial fibrillation increases the risk of suffering a stroke.
In the majority of people, atrial fibrillation is recurrent and progresses from self-terminating short episodes (paroxysmal), to longer
episodes (persistent) with the need for cardioversion into normal heart rhythm, or it can progress into permanent forms. Management
of atrial fibrillation includes control of symptoms, and reducing the risk of stroke. One strategy to achieve this is to restore the normal
heart rhythm by using medications. However, not all people respond well to heart rhythm drugs and therefore a newmedical procedure,
called ablation, using either a catheter or through surgery, has been developed to overcome this problem. The number of randomised
trials comparing heart rhythm drugs versus ablation is limited.
The aim of this systematic review is to compare the benefits and harms of ablation (using either catheter or surgery) to heart rhythm
drugs in people with persistent or long-standing persistent (non-paroxysmal) atrial fibrillation.
Study characteristics
We searched scientific databases from their inception to 1 April 2016 and found three studies where people are randomly allocated
into one of two or more treatment groups (known as randomised trials). The three trials included 261 adults (mean age: 60 years)
comparing catheter ablation (159 participants) to heart rhythm drugs (102) for non-paroxysmal atrial fibrillation at 12 months follow-
up.
Key results
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When compared to participants receiving heart rhythm drugs, those participants receiving catheter ablation were more likely to be free
from atrial fibrillation, had reduced risk of being hospitalised due to cardiac causes, and had a reduced risk of needing cardioversion after
12 months. There was uncertainty surrounding the effect of catheter ablation with significant bradycardia (or need for a pacemaker),
periprocedural complications, and other safety outcomes.
Quality of evidence
Evidence should be interpreted with caution as evidence quality ranged from moderate to very low across the different outcomes due
to the limitations of the original studies. It is likely that further high-quality and adequately powered trials may affect the confidence
in reported results.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Ablation compared to antiarrhythmic drugs for participants with non-paroxysmal atrial fibrillation
Population: people with non-paroxysmal atrial f ibrillat ion
Settings: hospital
Intervention: ablat ion
Comparison: ant iarrhythmic drugs
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Antiarrhythmic drugs Ablation
Freedom from atrial ar-
rhythmia
Follow-up: 12 months
Study population RR 1.84
(1.17 to 2.88)
261
(3 studies)
⊕⊕©©
low1,2
353 per 1000 649 per 1000
(413 to 1000)
M oderate population
429 per 1000 789 per 1000
(502 to 1000)
Participants needing car-
dioversion
Follow-up: 12 months
Study population RR 0.62
(0.47 to 0.82)
261
(3 studies)
⊕⊕⊕©
moderate2
422 per 1000 261 per 1000
(198 to 346)
M oderate population
500 per 1000 310 per 1000
(235 to 410)
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Cardiac hospitalisation
Hospitalisat ions direct ly re-
lated to ablat ion or ant iar-
rhythmic drugs
Follow-up: 12 months
Study population RR 0.27
(0.10 to 0.72)
216
(2 studies)
⊕⊕©©
low3
181 per 1000 49 per 1000
(18 to 130)
M oderate population
203 per 1000 55 per 1000
(20 to 146)
Significant bradycardia or
need for a pacemaker
Follow-up: 12 months
Study population RR 0.20
(0.02 to 1.63)
261
(3 studies)
⊕⊕©©
low4
49 per 1000 10 per 1000
(1 to 80)
M oderate population
0 per 1000 0 per 1000
(0 to 0)
Periprocedural complica-
tions and other safety out-
comes
Follow-up: 12 months
Study population RR 0.94
(0.16 to 5.68)
261
(3 studies)
⊕©©©
very low1,4
78 per 1000 74 per 1000
(13 to 445)
M oderate population
42 per 1000 39 per 1000
(7 to 239)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io.
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GRADE Working Group grades of evidence
High-quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate-quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low-quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low-quality: We are very uncertain about the est imate.
1 Unexplained heterogeneity; downgraded one level of evidence.
2 Serious imprecision due to low event rates compared to total part icipants; downgraded one level of evidence.
3 Very serious imprecision due to very low event rates compared to total part icipants; downgraded two levels of evidence.
4 Very serious imprecision due to very low event rates compared to total part icipants, with conf idence interval crossing line
of no ef fect; downgraded two levels of evidence.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Atrial fibrillation is currently the most common serious arrhyth-
mia, with a prevalence of 1% to 2% in the general population,
and the incidence increasing with age (Rahman 2014). In the ma-
jority of people, the disease is recurrent and progresses from being
paroxysmal (self-terminating short episodes) to a persistent (longer
episodes, need for cardioversion into normal sinus rhythm), or
permanent form (Kerr 2005). People with atrial fibrillation have
poorer outcomes and significantly poorer quality of life compared
with healthy controls, people with coronary heart disease (Dorian
2000), or the general population (Thrall 2006). Management of
atrial fibrillation includes reduction of stroke risk, control of symp-
toms, and prevention of tachycardia-induced cardiomyopathy. To
achieve the latter two, controlling the heart rate can be the pre-
ferred way to manage atrial fibrillation in some people (Wyse
2002), while others may require therapy to maintain normal si-
nus rhythm and prevent atrial fibrillation recurrence in order to
control their symptoms. Furthermore, restoration of sinus rhythm
improves both quality of life and exercise capacity (Singh 2006).
Therapy to maintain sinus rhythm includes antiarrhythmic drugs
or ablation procedures.
Description of the intervention
The use of catheter ablation for treatment of atrial fibrillation
based on electrical isolation of triggers from the pulmonary veins
has grown rapidly over the last decade (Jaïs 2008). Evidence from
randomised trials (mainly in people where antiarrhythmic drugs
have failed) indicates clear benefit for paroxysmal atrial fibrilla-
tion (Hakalahti 2015; Khan 2014; Morillo 2014; Nair 2009).
However, ablation success is reduced in people with persistent or
long-standing persistent (from now on referred to as ’non-parox-
ysmal’) atrial fibrillation, where it is associated with longer pro-
cedure duration and lower long-term success rates compared to
paroxysmal atrial fibrillation (Calkins 2012). Although guidelines
have suggested that operators should consider more aggressive ab-
lation strategies (including linear lesions and targeting of complex
fractionated electrocardiograms) for non-paroxysmal atrial fibril-
lation (Andrade 2012; Pokushalov 2013), recent evidence from
the STAR AF II trial has challenged this view (Verma 2015).
Current reported success rates for persistent atrial fibrillation vary
significantly between studies and the evidence is primarily derived
from non-randomised studies. Single-centre cohort studies have
reported a single procedure one-year atrial fibrilation-free survival
rate of less than 30% (Brooks 2010). Randomised trials com-
paring different ablation techniques have shown that pulmonary
vein isolation as a single procedure has a one-year atrial fibrila-
tion-free survival rate of around 40% (Elayi 2008; Oral 2005).
Adding linear ablation or targeting people with complex fraction-
ated atrial electrocardiograms (CFAEs) (or both) might increase
the reported success rate. However, the evidence for the efficacy
and safety of catheter ablation in non-paroxysmal atrial fibrilla-
tion comes primarily from analysis of case series. The largest and
longest case series (80 participants) reported a single procedure
success rate of around 50% using an aggressive ablation protocol
(Rivard 2012). The recent European Survey onMethodology and
Results of Catheter Ablation for Atrial Fibrillation, conducted in
72 medium- to high-volume centres (i.e. 50 or more atrial fibril-
lation ablations per year) from 10 European countries, reported
a 29.5% overall success rate of ablation at one year for persistent
atrial fibrillation (Arbelo 2014).
Endocardial catheter-based techniques for atrial fibrillation abla-
tion initially used radiofrequency energy sources. Newer energy
sources have now evolved, which include cryoenergy, laser, and
high frequency ultrasound (Cappato 2010). Surgical techniques,
such as the epicardial approach, as well as hybrid surgical and en-
docardial techniques previously involved the Cox maze procedure
but now increasingly utilise radiofrequency energy or cryoabla-
tion, either intraoperatively during open surgery or via an epicar-
dial approach. Some of these techniques have been assessed in ei-
ther observational studies or randomised trials (Calkins 2012).
How the intervention might work
Ablation to prevent atrial fibrillation is primarily based on electri-
cal isolation of triggers, mainly premature atrial beats and atrial
tachycardia arising from the pulmonary veins at the venous ostium
or around the antral area of the veins (Haïssaguerre 1998). Pul-
monary vein isolation is therefore the mainstay of therapy. While
pulmonary vein isolation is effective in people with paroxysmal
atrial fibrillation, it is less effective in people with non-paroxysmal
atrial fibrillation, and therefore a variety of complementary abla-
tion targets have been investigated including lines, CFAE map-
ping, and rotors to increase the success of catheter ablation of atrial
fibrillation (Andrade 2012; Narayan 2012). These ablation strate-
gies are thought to either compartmentalise the atria or reduce the
critical mass of tissue required formaintenance of atrial fibrillation
(lines), or they are thought to represent sites of atrial fibrillation
rotors (CFAE). However, there is no robust evidence that adding
other targets to pulmonary vein isolation is beneficial. Recently
there have been developments in signals processing and mapping
techniques to target rotors thought to be the extra-pulmonary vein
sources of atrial fibrillation maintenance (Narayan 2012). Other
approaches have been reported in a few trials, including targeting
of the cardiac autonomic system (ganglionated plexi ablation) and
ablation of the ganglionic plexi alone or in conjunction with pul-
monary vein isolation (Kottkamp 2015).
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Why it is important to do this review
The best rhythmmanagement strategy for people with non-parox-
ysmal atrial fibrillation is currently not well defined. Antiarrhyth-
mic drugs have been the mainstay of therapy, however a meta-
analysis of non-randomised and randomised studies of all antiar-
rhythmic drugs showed an average success rate for prevention of
atrial fibrillation recurrence of 52% over one year (Calkins 2009).
In addition, antiarrhythmic drugs have serious side effects in-
cluding ventricular arrhythmias and lung disease (Singh 2005).
Non-pharmacological interventions (catheter and surgical abla-
tion techniques) have been developed as alternatives to maintain
sinus rhythm in people with atrial fibrillation. Several interna-
tional society practice guidelines recommend both antiarrhythmic
drugs as well as radiofrequency catheter ablation (RFCA) as ac-
ceptable options for rhythm control in people with atrial fibril-
lation (Calkins 2012; Camm 2012). However, there has been a
tremendous upsurge in the use of RFCA, driven by the idea that
it is a better therapy and that it might change the natural history
of the disease. This has the potential to have a significant impact
on health systems worldwide (Kneeland 2009; Kumar 2013).
Antiarrythmic drugs are perceived to be a less acceptable thera-
peutic option, despite being more readily available and cheaper,
and possibly being more effective in particular groups of people
with atrial fibrillation (Kumar 2013). With the diversification of
atrial fibrillation ablation techniques, an analysis of efficacy out-
comes and safety is critical to inform the field and help identify
optimal treatment strategies. Several systematic reviews have been
conducted over recent years, but these have concentrated mainly
on paroxysmal atrial fibrillation (Cheng 2014; Khan 2014; Nault
2010).When non-paroxysmal atrial fibrillation has been the focus
of attention, reviews have included non-randomised studies and
case series, with largely inconclusive results (Calkins 2009). In ad-
dition, none of the previous reviews have used state-of-the-art sys-
tematic review methods, such as those implemented by Cochrane.
Therefore, there is a need for a de novo systematic review using
Cochrane recommended methods to evaluate the efficacy and sa-
fety of ablation (catheter and surgical) versus antiarrhythmic drugs
in non-paroxysmal atrial fibrillation. This will help to inform the
adoption of an optimal treatment strategy.
O B J E C T I V E S
To determine the efficacy and safety of ablation (catheter and sur-
gical) in people with non-paroxysmal (persistent or long-standing
persistent) atrial fibrillation compared to antiarrhythmic drugs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised trials of parallel-group design with
the individual as the unit of randomisation. All studies had at least
12 months of follow-up.
Types of participants
We included three studies with adults aged 18 years and over with
persistent atrial fibrillation (defined as lastingmore than seven days
or requiring termination by cardioversion either with drugs or by
direct current cardioversion) or long-standing persistent atrial fib-
rillation (defined as lastingmore thanone yearwhen it is decided to
adopt a rhythm control intervention), regardless of any concomi-
tant underlying heart disease. Where studies had a mixed popu-
lation, at least 50% of participants should have had either persis-
tent or long-standing persistent atrial fibrillation (Forleo 2009).
If studies had 50% or more participants with paroxysmal atrial
fibrillation, we contacted the authors to obtain information on the
participants with only non-paroxysmal atrial fibrillation (Stabile
2006).
Types of interventions
We included trials using the radiofrequency catheter abla-
tion (RFCA) technique. The comparison was approved an-
tiarrhythmic drugs, which includes any of the following: fle-
cainide, propafenone, quinidine, amiodarone, sotalol, dofetilide,
or dronedarone.
We excluded all studies where the comparator was rate control
and excluded concomitant surgical ablation studies (that is, surgi-
cal atrial fibrillation ablation done during open heart surgery for
another indication or condition).
Types of outcome measures
We defined outcome measures according to a recent consensus
statement regarding randomised trials in atrial fibrillation. Where
atrial fibrillation was defined as a common supraventricular ar-
rhythmia that is characterised by chaotic contraction of the atrium,
needing an electrocardiogram (ECG) recording for its diagno-
sis (Calkins 2012). We evaluated the following outcomes at 12
months and for the longest term available.
Primary outcomes
1. Freedom from atrial arrhythmias (i.e. atrial fibrillation,
atrial flutter, or atrial tachycardia) or recurrence of any atrial
arrhythmias
2. Participants needing cardioversion
3. Cardiac hospitalisation
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Secondary outcomes
1. All-cause mortality
2. Fatal or non-fatal stroke
3. Any embolic complication
4. Combined endpoint of any major adverse cardiac event
(MACE)
5. Significant bradycardia or need for a pacemaker
6. Health-related quality of life measured by a validated scale
7. Cost
8. Periprocedural complications and other safety outcomes
Periprocedural complications andother safety outcomes here refers
to adverse events and/or complications arising from ablation e.g.
pericarditis, pericardial effusion, minor vascular access complica-
tions.
Search methods for identification of studies
Electronic searches
We searched the following sources from their inception. Which
also includes the year the first ablation procedure was performed
to the specified date, and placed no restrictions on language of
publication.
• CENTRAL; Issue 2 of 12, March 2016 (the Cochrane
Library)
• MEDLINE (OVID 1946 to February week 4 2016)
• EMBASE (OVID, 1980 to 2016 week 09)
• Health Technology Assessment Database; Issue 1 of 4,
January 2016
• Conference Proceedings Citation Index-Science (CPCI-S);
1990 to present (Web of Science)
• ClinicalTrials.gov (clinicaltrials.gov; searched 1 April 2016)
• World Health Organization International Clinical Trials
Registry Platform (who.int/ictrp/en; searched 3 March 2016)
We adapted the preliminary search strategy forMEDLINE (Ovid)
for use in the other databases.We applied theCochrane sensitivity-
maximising RCT filter toMEDLINE (Ovid) and adapted it to the
other databases (Lefebvre 2011), except CENTRAL. For details
of terms used in search strategies please see Appendix 1.
Searching other resources
We identified other potentially eligible trials or ancillary publi-
cations by handsearching the reference lists of retrieved included
trials, systematic reviews, meta-analyses, and health technology as-
sessment reports. We also contacted study authors of included or
registered trials to identify any further studies wemay havemissed.
Data collection and analysis
Selection of studies
Two review authors (JN, OO) independently screened titles and
abstracts for inclusion of all the potential studies. We retrieved the
full-text study reports/publication and three authors (JN,OO and
AJA) independently screened the full-text and identified studies
for inclusion; any disagreement was resolved with consultation
between the other review authors (GA, CAM and JPC). We have
presented a PRISMA flow diagram showing the process of study
selection (Figure 1).
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Figure 1. Study flow diagram.
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Data extraction and management
We extracted the following study characteristics.
1. Methods: study design, study duration, length of follow-up,
details of any ’run in’ period, number of study centres and
location, study setting, withdrawals, and date of study.
2. Participants: number, mean age, age range and standard
deviation (SD), gender, severity of condition, diagnostic criteria,
smoking history, underlying heart disease conditions, left atrial
size (mean and SD) proportion of normal/abnormal, duration of
atrial fibrillation (mean and SD), inclusion criteria, and
exclusion criteria.
3. Interventions: type of ablation and technique used,
comparisons, concomitant medications, and excluded
medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported. We extracted both numbers
of events and means as well as estimated effect sizes and 95%
confidence intervals (CIs).
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
For studies that met our inclusion criteria, two review authors
(JN, OO) independently extracted data from the trials and trans-
ferred the data into a pro forma with any disagreements resolved
by discussion, by consultation with a third review author (GA),
or, when required, by contacting authors of included studies. We
tried to find the protocol of each included study and report pri-
mary, secondary, and other outcomes in comparison with data in
publications.
Assessment of risk of bias in included studies
Two review authors (JN, OO) independently assessed risk of bias
for each included study. We resolved disagreements by consulta-
tion with a third review author (GA or JPC) or by general consen-
sus. We applied the Cochrane ’Risk of bias’ tool to the following
domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias (e.g. industry funding).
We judged each potential source of bias as ’high’, ’low’ or ’un-
clear’ and provided quote(s) from the study report together with
justification(s) for our judgement in the ’Risk of bias’ table. We
summarised the ’Risk of bias’ judgements across different studies
for each of the domains listed. When considering the treatment
effects, we took into account the risk of bias for the studies that
contributed to that outcome. We considered the implications of
missing outcome data from individual participants per outcome,
such as high dropout rates (for example, above 15%) or disparate
attrition rates (for example, a difference of 10% or more between
study arms).
Measures of treatment effect
We expressed dichotomous outcome data as risk ratios (RRs) with
95%CIs.We analysed all included studies using intention-to-treat
analyses.
Unit of analysis issues
All included trials were randomised at the individual participant
level.
Dealing with missing data
We contacted authors of included studies to obtain missing nu-
merical outcome data and to verify key study characteristics, where
possible. Where this was not possible, and the missing data were
thought to introduce serious bias, we considered exploring the im-
pact of including such studies in the overall assessment of results
by conducting sensitivity analyses. We also obtained information
from trial registries. For trials wheremore than 50%of participants
had paroxsymal atrial fibrillation, we contacted the trial authors
to obtain data on non-paroxsymal participants. We then included
the data obtained in our analyses.
Assessment of heterogeneity
We identified heterogeneity through visual inspection of the forest
plots and by using a standard Chi² test with a significance level of
α = 0.1. We also use the I² statistic to quantify the heterogeneity
across trials. We attempted to determine possible reasons for het-
erogeneity by examining individual studies and subgroup charac-
teristics.
Assessment of reporting biases
We were unable to assess small-study bias as the number of in-
cluded studies was not sufficient for an informative funnel plot
(Higgins 2011).
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Data synthesis
Weundertookmeta-analyses if the participants, interventions, and
the comparisons were similar enough for pooling to be appropriate
(Wood 2008). If I² is less than or equal to 40%, we used a fixed-
effect model, whereas if the I² statistic was greater than 40%,
we used both the fixed-effect and random-effects model (Higgins
2011), but reported results from the random-effects model.
The quality of evidence was evaluated using the GRADE ap-
proach (Higgins 2011) and the GRADE profiler (GRADEPRO)
3.6 (GRADEpro GDT) was employed to import data from Re-
viewManager 5.3 (RevMan 2014) to create ’Summary of findings’
table (Summary of findings for the main comparison). Outcomes
reported in the summary of findings table include:
• Freedom from atrial arrhythmia
• Participants needing cardioversion
• Cardiac hospitalisation
• significant bradycardia or need for a pacemaker
• Periprocedural complications and other safety outcomes
Subgroup analysis and investigation of heterogeneity
We planned on conducting a subgroup analysis, however due to
the small number of included studies we were unable to do so.
Sensitivity analysis
We planned on conducting a sensitivity analysis, however due to
the small number of included studies we were unable to do so.
R E S U L T S
Description of studies
Results of the search
Appendix 1 outlines the search strategies, and Figure 1 includes the
PRISMA flow chart depicting numbers of included and excluded
studies. After de-duplication, the search resulted in 5714 results,
of which we excluded 5689 records as theywere not relevant to our
review question.We assessed 25 full-text articles for eligibility. Five
out of these 25 studies had a mix of atrial fibrillation participants,
with more than 50% having paroxysmal atrial fibrillation. We
contacted authors for data on non-paroxysmal atrial fibrillation
cases. We only received information from the Stabile 2006 trial.
We excluded 18 studies and reasons for full-text exclusion are
shown in Characteristics of excluded studies.
We also identified one study awaiting classification
(NCT00821353), and three ongoing studies (NCT00196209;
NCT00911508; NCT01420393). The study awaiting classifica-
tion compares radiofrequency catheter ablation with rhythm con-
trol in participants with hypertrophic cardiomyopathy and parox-
ymal or chronic atrial fibrillation (NCT00821353). This trial was
yet to be published when this review was developed, with no study
result posted. Details are outlined in the Characteristics of studies
awaiting classification section. Although we identified three on-
going studies, the comparison arm used in NCT00196209 and
NCT01420393 was not antiarrhythmic drugs. NCT01420393
compared ablation versus rate control, while NCT00196209
compared catheter ablation versus external electric cardioversion.
NCT00911508 compared rate control or rhythm control drug
therapy for atrial fibrillation to catheter ablation. Details are out-
lined in the Characteristics of ongoing studies section.
A total of three studies were suitable for inclusion.
Included studies
A summary description of studies included is reported in
Characteristics of included studies. Studies were published be-
tween 2006 and 2014. Of the three randomised trials included
(Forleo 2009; Mont 2014; Stabile 2006), one was conducted in
Spain (Mont 2014), and two in Italy (Stabile 2006; Forleo 2009).
With the exception of Forleo 2009, all studies were prospec-
tively registered (ClinicalTrials.gov identifier: NCT00227344 and
NCT00863213). The total number of participants included was
261 (mean age: 60 years) comparing radiofrequency catheter abla-
tion (RFCA) (159 participants) with antiarrhythmic drugs (102).
Though we set out to include trials with outcomes evaluated at 12
months or for the longest term available, most trials reported a fol-
low-up of 12 months, except Stabile 2006 that reported a median
of 18 months of follow-up. The majority of participants recruited
were male, with the percentage of women ranging from 11.6% to
40.9%. All trials included participants that have not responded to
antiarrhythmic drug therapy. Further details of included studies
and the characteristics of participants included in the studies are
described in Table 1 and Table 2, respectively.
In all three trials, ablation was through radiofrequency to isolate
the pulmonary veins and details of the specific technique used
in the three trials are described in Table 1. The need for a sec-
ond ablation (due to recurrent atrial fibrillation or flutter within
the blanking period) was reported in 8.2% of the participants in
Mont 2014. In all trials, the ablation group also received antiar-
rhythmic drugs mainly during the blanking period (range: 1 to 3
months after ablation) with the exception of Stabile 2006, where
the antiarrhythmic drugs were used throughout the duration of
the study (Personal communication from Study authors Bertaglia
2015 [pers comm]). In the antiarrhythmic drug arm (compari-
son), the decision on the specific antiarrhythmic drug was based
on recommended guidelines or physician preference with amio-
darone (Stabile 2006: 66%; Forleo 2009: 63%; and Mont 2014:
46%) being the most commonly used antiarrhythmic drug. Full
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details of interventions can be found in Table 1.
Excluded studies
We excluded 18 studies on second pass and 5711 studies in total
(Figure 1). Reasons for exclusion were mainly due to studies not
addressing prespecified population, intervention, and comparison
characteristics. Excluded studies were either on paroxysmal atrial
fibrillation, rate control, or on concomitant surgical ablation stud-
ies. For studies with a mixed population of atrial fibrillation, with
more than 50% having paroxysmal atrial fibrillation, we contacted
authors for data on only non-paroxysmal atrial fibrillation cases.
If data were not provided as requested, we excluded these studies.
Full details of 18 studies excluded on second pass can be found in
Characteristics of excluded studies.
Risk of bias in included studies
Figure 2 and Figure 3 demonstrate the overall and trial specific
information on risk of bias.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The risk of bias was low for sequence generation, and unclear for
allocation concealment in all studies. We judged allocation to be
unclear because information from study authors was not available
to clarify the allocation.
Blinding
Given the nature of the intervention, blinding of participants and
personnel was not possible. This makes it difficult to judge the di-
rection of effect due to blinding. Therefore, we considered the risk
of performance bias to be unclear. However, blinding of outcome
assessment was unclear for two of the included studies ( Forleo
2009 and Stabile 2006) and low for Mont 2014.
Incomplete outcome data
Regarding, Intention-to-treat used, attrition bias, and losses to
follow-up, we judged all trials to be at low risk.
Selective reporting
We judged all three trials to be at low risk of outcome reporting
bias for our primary outcomes. We judged two studies at low risk
for all secondary outcomes (Mont 2014; Stabile 2006).
Other potential sources of bias
Regarding other potential biases, Mont 2014 was terminated be-
fore reaching the planned sample size due to a lower than expected
recruitment rate, resulting in a loss of statistical power. However,
the study authors claim that the difference between groups in the
primary endpoint was higher than assumed in the sample size cal-
culation, which likely compensated for the loss of statistical power
in the sample size. Apart from theMont 2014 trial, no other study
was sponsored by industry (Medtronic and Biosense Webster).
One of the investigators from Forleo 2009 reported to have re-
ceived lecture fees from Industry.
Effects of interventions
See: Summary of findings for the main comparison Ablation
compared to antiarrhythmic drug for participants with non-
paroxysmal atrial fibrillation
The main result findings are reported in Summary of findings
for the main comparison. Analysis 1.1, Analysis 1.2, Analysis 1.3,
Analysis 1.4, Analysis 1.5, Analysis 1.6, and Analysis 1.7 describe
the forest plots for the efficacy and safety of ablation for people
with non-paroxysmal atrial fibrillation for various outcomes.
Primary outcomes
Freedom from atrial arrhythmias or recurrence of any atrial
arrhythmias
All three trials reported information on this outcome. All studies
included a blanking period and any atrial fibrillation or flutter
detected during this period was not included in the analysis. The
definition of atrial arrhythmias, mode of ascertainment, and fre-
quency of evaluation to detect an atrial arrhythmia varied consid-
erably by study (details are reported inTable 3). After pooling data,
radiofrequency catheter ablation (RFCA) increased freedom from
atrial arrhythmias at 12 months compared with antiarrhythmic
drugs (risk ratio (RR) 1.84, 95% confidence interval (CI) 1.17 to
2.88; 3 studies, 261 participants; low-quality evidence) (Analysis
1.1). We judged the quality of evidence as low as a result of un-
explained heterogeneity and imprecision due to small event rates
compared to total participants (Summary of findings for the main
comparison).
Participants needing cardioversion
All three studies reported information on this outcome. However,
Forleo 2009 reported zero participants needing cardioversion after
the blanking period in both arms. Only the event data fromMont
2014 and Stabile 2006 contributed to the meta-analysis. After
pooling data from these studies, participants randomised to RFCA
had a reduced risk of needing cardioversion (RR 0.62, 95% CI
0.47 to 0.82); I2 = 20%, 3 studies, 261 participants; moderate-
quality evidence) (Analysis 1.3). As a result of imprecision due
to small event rates compared to total participants, we judged
the quality of evidence to be of moderate-quality (Summary of
findings for the main comparison) .
Cardiac hospitalisation
Forleo 2009 and Mont 2014 provided the event data for cardiac
hospitalisation and result findings showed evidence of catheter ab-
lation reducing the risk of cardiac hospitalisation (RR 0.27, 95%
CI 0.10 to 0.72; I2 = 0%, 2 studies, 216 participants; low-quality
evidence) (Analysis 1.4). However, Mont 2014 only reported on
atrial fibrilation-related hospitalisations. Stabile 2006, when con-
tacted (Bertaglia 2015 [pers comm]), reported no data specifically
on cardiac hospitalisations, but only data on all hospitalisations
as follows: ablation median of 1 (interquartile range (IQR): 1, 2)
and antiarrhythmic drug arm median of 2 (IQR: 1, 2), this in-
cludes the hospitalisations required for ablation. Thus, we judged
data from Stabile 2006 not suitable for meta-analysis. As a result
of significant imprecision due to small event rates compared to
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total participants, we judged the quality of evidence to be low
(Summary of findings for the main comparison).
Secondary outcomes
Significant bradycardia or need for a pacemaker
All three studies reported on this outcome. However studies by
Mont 2014 and Stabile 2006 reported zero events in either arm.
Only the event data from Forleo 2009 contributed to the meta-
analysis. Result findings showed substantial uncertainty surround-
ing the summary estimate (RR 0.20, 95% CI 0.02 to 1.63; 3
studies, 261 participants; low-quality evidence) (Analysis 1.5). As
a result of imprecision with confidence intervals crossing the ’no
effect’ line, we judged the quality of evidence to be low (Summary
of findings for the main comparison).
Periprocedural complications and other safety outcomes
All three studies reported event data on this outcome. Periprocedu-
ral complications and other safety outcomes reported were adverse
events and/or complications arising from ablation, e.g. pericardi-
tis, pericardial effusion, and minor vascular access complications.
Result findings showed that RFCA showed no effect with peripro-
cedural complications and other safety outcomes compared with
antiarrhythmic drugs (RR 0.94, 95% CI 0.16 to 5.68; 3 studies,
261 participants; very low-quality evidence) (Analysis 1.6). As a
result of imprecision due to small event rates with confidence in-
tervals crossing the ’no effect’ line, and unexplained heterogeneity,
we judged the quality of evidence to be very low (Summary of
findings for the main comparison).
All-cause mortality
Two trials reported all-cause mortality. In the Mont 2014 study,
authors reported that no death was observed in either arm after
12 months of follow-up, while the cause of death in Stabile 2006
was gastrointestinal haemorrhage (information provided by the
authors). Given the extremely low number of events (N = 1 for
Stabile 2006) and the absence of events in the comparison arm,
we decided not to pool the results for this outcome.
Fatal or non-fatal stroke
Information on stroke was reported in two studies (Mont 2014;
Stabile 2006), and they both reported zero stroke events in either
arm.
Any embolic complication
All three included studies reported zero embolic complications in
either arm (Forleo 2009; Mont 2014; Stabile 2006).
Combined endpoint of any major adverse cardiac event
(MACE)
None of the included studies reported on the combined endpoint
of MACE.
Health-related quality of life
All studies, except Stabile 2006 reported this outcome, but used
different tools. In Forleo 2009, the information reported was not
suitable formeta-analysis and not available from the study authors.
Forleo 2009 used the Medical Outcomes Study 36-item short-
form health survey (SF-36) to evaluate quality of life and reported
improvements in the mean change in quality of life scores in the
ablation arm compared with the mean change in quality of life
scores in the antiarrhythmic drug arm for five out of eight SF-
36 subscales. However, this was only reported as “P < 0.05, PVI
versus ADT group” which is insufficient for meta-analysis. Mont
2014 used an atrial fibrillation-quality of life questionnaire and
authors reported no difference in the global score of quality of life
between the two arms at six months (5.5, 95% CI -2.3 to 13.4) or
12 months (3.8, 95% CI -5.2 to 12.8). Likewise, no differences
were observed for the physical, psychological, and sexual domains.
Cost
None of the three included trials reported on cost. However,
screening identified one cost-effectiveness study from the perspec-
tive of the UK National Health Service (NHS) (McKenna 2008).
This study examined the cost-effectiveness of RFCA compared
with antiarrhythmic drugs in adults with paroxysmal atrial fib-
rillation predominantly refractory to at least one previous antiar-
rhythmic drug. The antiarrhythmic drug considered was amio-
darone. The efficacy of the intervention included in the cost-ef-
fectiveness models was derived from trials where the majority of
the participants had paroxysmal atrial fibrillation, therefore the
findings from this analysis are not applicable to people with non-
paroxysmal atrial fibrillation.
D I S C U S S I O N
Summary of main results
The main findings of this systematic review and meta-analysis
in people with non-paroxysmal atrial fibrillation who have not
responded to antiarrhythmic drug therapy suggest that radiofre-
quency catheter ablation (RFCA) is superior to antiarrhythmic
drugs in achieving freedom from atrial arrhythmias, reducing the
need for cardioversion, and reducing cardiac hospitalisation at 12
months. There was substantial uncertainty surrounding the effect
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of RFCA on significant bradycardia (or need for a pacemaker) and
no effect on total mortality, stroke, embolic complications, or any
major adverse cardiac event. Result findings should be interpreted
with caution, as the quality of the evidence was at the very best
moderate, mainly due to extremely low numbers of outcomes in
the pooled analysis together with substantial heterogeneity within
included studies (Summary of findings for the main comparison).
Overall completeness and applicability of
evidence
Despite the widespread use of RFCA as treatment for non-parox-
ysmal atrial fibrillation, only three trials with 261 participants that
fulfilled the inclusion criteria were eligible. Most of the studies
were performed before the definition of ’long-standing persistent’
was introduced. TheMont 2014 study excluded participants with
long-standing persistent atrial fibrillation, while the other two in-
cluded studies had a mixed population of persistent and long-
standing persistent atrial fibrillation (Forleo 2009; Stabile 2006),
without the ability to differentiate the two. All studies were con-
ducted in high-income countries, and due to strict selection crite-
ria of participants included in these studies, the applicability of this
evidence to certain groups is limited. These groups are women, el-
derly (> 70 years), people with comorbidities, and people naive to
antiarrhythmic drugs. Likewise, it is important to note that (with
the exception of Mont 2014) included studies were designed and
started recruitment more than 10 years ago, and all use a single
source of energy, namely RFCA. Not a single surgical ablation
trial was eligible, and therefore, although aiming to broaden the
evidence, this systematic review and meta-analysis only compared
RFCA with antiarrhythmic drugs. Furthermore, novel technolo-
gies such as contact force catheters were not included. Evidence
should be interpreted with caution, as event rates were low across
reported outcomeswith the quality of evidence ranging frommod-
erate to very low.
Quality of the evidence
The quality of evidence, using the GRADE approach and
GRADEpro (GRADEpro GDT), for efficacy and safety of abla-
tion for people with non-paroxysmal atrial fibrillation versus an-
tiarrhythmic drugs is reported in Summary of findings for the
main comparison. The quality ranged from moderate to very low
across the different outcomes. This was mainly due tomoderate to
substantial heterogeneity and imprecise results due to extremely
low numbers of events for outcomes analysed.
It is important to highlight certain limitations in terms of design of
the included trials. The definitions of their primary outcome (free-
dom from atrial arrhythmias) including the frequencies and mon-
itoring strategies to detect atrial fibrillation or flutter varied for the
three included trials (Table 3). Two of the included trials (Forleo
2009; Stabile 2006), predated the current monitoring and atrial
fibrillation recurrence recommendations suggestedwhen conduct-
ing randomised trials evaluating the efficacy of RFCA (Calkins
2012). This could have led to under-reporting of arrhythmia re-
currence, though unlikely to introduce systematic bias (due to
randomised design) this might have reduced statistical power in
included studies. Moreover, there was no information on the re-
currence of atrial fibrillation according to whether or not these
were symptomatic. These issues highlight the need for adherence
to internationally agreed definitions of atrial fibrillation ablation
success. A further limitation of these studies is that efficacy of per-
sistent ablation remains suboptimal for a single procedure, aver-
aging about 50% maintenance of sinus rhythm. This limits the
ability of many studies to fully establish the procedures’ efficacy
due to the fact that at least 30% require a repeat intervention to
maintain sinus rhythm, with the cumulative risk of complications
and additional hospitalisations, plus the lag in ensuing follow-up.
Most studies have only objectively evaluated the participants in
the one-year window postprocedure, when further intervention
means that very often they may be in the first three- to six-month
follow-up phase of the second procedure. This makes evaluating
the full balanced comparisons of outcomes challenging.
Potential biases in the review process
We followed the methods as outlined in the published Cochrane
protocol (Amit 2016). The methodological and search strategies
were rigorous and comprehensive and we consider it unlikely that
wemissed substantial trials. In order tominimise the consequences
of reporting bias, we contacted study authors, asking for necessary
information when this was, either, not available or inadequately
reported. By applying this strategy we obtained unpublished data
from the Stabile 2006 study relevant only to non-paroxsymal atrial
fibrillation participants for both primary and secondary outcomes.
With the exception of the outcomes not reported in the Summary
of findings for the main comparison, all analysed primary and
secondary outcomes in this review were adequately reported by all
identified trials.
Agreements and disagreements with other
studies or reviews
Current practice guidelines vary on their recommendations for
RFCA in people with non-paroxsymal atrial fibrillation; the Eu-
ropean Society of Cardiology (ESC) guideline recommendation
class for persistent symptomatic atrial fibrillation that is refractory
to antiarrhythmic drugs is IIa; this was not updated in the 2012
ESC guidelines for the management of atrial fibrillation (Camm
2012). The recent Wynn 2014 systematic review and meta-anal-
ysis that included both randomised and non-randomised trials,
reported a benefit for RFCA of reducing atrial fibrillation recur-
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rence (odds ratio (OR) 0.32, 95% confidence interval (CI) 0.20
to 0.53). Our findings are in agreement with previous reviews, al-
though reporting a more modest effect in favour of RFCA regard-
ing atrial fibrillation recurrence. In contrast to theWynn 2014 re-
view, we expanded the coverage of clinical outcomes and observed
a significant reduction in the need for cardioversion and hospitali-
sation, which may be relevant in terms of reducing health resource
utilisation. However, the importance of these findings is weak-
ened by the overall quality of the evidence; moderate-quality for
participants needing cardioversion and low-quality for hospitalisa-
tion. Additional outcomes included in this review, not covered by
previous systematic reviews, were total mortality, stroke, embolic
complications, and any major adverse cardiac event (MACE). Un-
fortunately the number of events in included trials was too low
to preclude any reliable conclusion on the effects that RFCA may
have on these outcomes.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The available evidence suggests that radiofrequency catheter abla-
tion (RFCA) is effective in restoring andmaintaining sinus rhythm
as well as reducing both cardioversion and cardiac hospital admis-
sions in younger people (mean age 60 years) with primarily non-
paroxysmal atrial fibrillation who have not responded to antiar-
rhythmic drug therapy with 12 months follow-up. However, qual-
ity of the evidence was moderate at the very best. Current practice
suggests that RFCA is being recommended in this younger pop-
ulation, despite lack of strong evidence (Cappato 2010). Personal
choice, benefit and risk, supported by an atrial fibrillation heart
team should be considered, also bearing in mind the stated limita-
tions with included studies and the quality of reported outcomes.
Further high-quality research is needed to improve the selection
of people that will benefit the most from RFCA.
Implications for research
Based on the quality of the evidence reported, moderate-quality
at the very best, it is very likely that further adequately powered
and high-quality randomised trials will have an impact on our
confidence in the current estimates of effect that RFCA has on
people with non-paroxsymal atrial fibrillation. Key characteristics
of these high-quality randomised trials should include standard-
ised methods for monitoring rhythm, longer follow-up, broader
selection of participants (in particular at high risk of hard end-
points), larger sample size, use of stricter endpoints in terms of
success of ablation, and use of validated quality of life instruments
more suited to participants with atrial fibrillation. The impact of
RFCA on health resource utilisation (cost-effectiveness) also needs
to be consistently captured in future randomised trials; we expect
the ongoing CABANA trial to provide some information in this
regard (NCT00911508).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Forleo 2009
Methods RCT
Participants Country: Italy
Inclusion criteria: Diabetes mellitus 2 participants with symptomatic paroxysmal or
persistent AF for ≥ 6 months refractory to ≥ 1 class 1-3 antiarrhythmic drugs
Exclusion criteria:
• Age < 18 or > 75 years
• Ejection fraction < 30%, left atrial size > 55 mm
• Absence of informed participant consent.
• Any condition that would make survival for 1 year unlikely.
• Participants with prior cardiac surgery as well participants with history of previous
ablation for AF.
Randomised: Control: 35, Intervention: 35
Age (mean in years): Control: 64.8, Intervention: 63.2
%Male gender: Control: 23, Intervention: 20
Interventions Control: New ADT. In participants with persistent AF, cardioversion was performed
under a new ADT to maintain the sinus rhythm
5-week blanking period.
Intervention: Pulmonary vein isolation. Participants were discharged on antiarrhythmic
drugs
Outcomes Analysis was by intention-to-treat.
Primary outcomes
1. Freedom from atrial arrhythmias
Control: 15/35, Intervention: 28/35
2. % Needing cardioversion after blanking period
Control: 0/35, Intervention: 0/35
Notes Persistent AF was not self-terminating within 7 days and permanent AF if cardioversion
had failed or had not been attempted. Pilot study and not adequately powered
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible participants were randomised to receive either pul-
monary vein isolation or a new ADT according to a computer-
generated study list
Allocation concealment (selection bias) Unclear risk Method for allocation concealment not specified by authors.
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Forleo 2009 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk OpenRCT. Not possible to blind participants receiving ablation
due to the nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk At each visit, participants were asked whether medical events
or symptoms suggestive of cardiac arrhythmias occurred and an
ECG Holter Monitoring was performed to detect the presence
of asymptomatic arrhythmias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up.
Selective reporting (reporting bias) Low risk No evidence of selective reporting. Pre-specified outcomes re-
ported
Other bias Unclear risk Pilot study and not adequately powered.
Mont 2014
Methods RCT
Participants Country: Spain
Inclusion criteria: Participants with symptomatic persistent atrial fibrillation (> 7 or <
7 days requiring electrical or pharmacological cardioversion) refractory to at least one
class I or class III antiarrhythmic drug
Exclusion criteria:
• Age < 18 or > 70 years
• Long-standing persistent AF (> 1 year of continuous AF)
• First episode of AF
• Hyper- or hypothyroidism
• Hypertrophic cardiomyopathy
• Implanted pacemaker or defibrillator
• Moderate or severe mitral disease or mitral prosthesis
• Left ventricular ejection fraction < 30%
• Left atrial diameter > 50 mm
• Prior ablation procedure
• Contraindication for oral anticoagulation
• Left atrial thrombus
• Active infection or sepsis
• Pregnancy
• Unstable angina
• Acute myocardial infarction during previous 3 months
• Life expectation < 12 months
• Current participation in another clinical trial
• Mental disease or inability to give informed consent
• Disease contraindicating ablation or ADT
Randomised: Control: 48, Intervention: 98
Age (mean in years): Control: 55, Intervention: 55
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Mont 2014 (Continued)
%Male gender: Control: 77, Intervention: 77.5
Interventions Control: Participants were treated depending on physician’s choice and according to
current guidelines. Discontinuation of the antiarrhythmic treatment was not required
before inclusion in the ADT group. There was no predefined protocol on the use of
ADT during the blanking period
Intervention: Pulmonary vein ablation. Antiarrhythmic drugs were discontinued ≥ 5
half-life periods (or ≥ 1 week for amiodarone) before ablation; antiarrhythmics were
reinitiated immediately after CA for the blanking period
3-month blanking period.
Outcomes Analysis was by intention-to-treat
Primary outcomes
1. Freedom from atrial arrhythmias
Control: 43.7%, Intervention: 70.4%
2. % Needing cardioversion after blanking period
Control: 50, Intervention: 34.7
Notes Possible loss of statistical power as study was terminated before reaching planned sample
size due to lower than expected recruitment rate. The study was supported by an unre-
stricted grant fromMedtronic and Biosense Webster. FB was supported by a grant from
Hospital Clinic (premi de Fi de Residencia Emili Letang). No other potential conflict of
interest relevant to this study was reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Recruited participants were randomly assigned to either ablation
(CA group) or medical therapy (ADT group) according to a 2:
1 blocked randomisation list stratified by centre
Allocation concealment (selection bias) Unclear risk Method for allocation concealment not specified by authors.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk OpenRCT. Not possible to blind participants receiving ablation
due to the nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded. The primary endpoint was as-
sessed by an independent endpoint committee, which evaluated
the episodes based on the information received
Incomplete outcome data (attrition bias)
All outcomes
Low risk 83 participants (84%) in intervention group provided outcome
data compared to all of the control group
Selective reporting (reporting bias) Low risk No evidence of selective reporting. Pre-specified outcomes were
reported
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Mont 2014 (Continued)
Other bias High risk Loss of statistical power. Study was terminated before reaching
the planned sample size due to a lower than expected recruit-
ment rate (study limitations) though authors claim that “the
difference between groups in the primary endpoint was higher
than assumed in the sample size calculation, which likely com-
pensated for the loss of statistical power.”
Stabile 2006
Methods RCT
Participants Country: Italy
Inclusion criteria: Participants with paroxysmal or persistent AF who were intolerant of
antiarrhythmic drugs or in whom two or more antiarrhythmic drug regimens had failed
Exclusion criteria:
• Age < 18 or > 80 years
• Permanent AF (AF was the sole rhythm for the last 12 months)
• AF secondary to a transient or correctable abnormality, including electrolyte
imbalance, trauma, recent surgery, infection, toxic ingestion, and endocrinopathy
• Persistence of AF episodes triggered by another uniform arrhythmia (i.e. atrial
flutter or atrial tachycardia) despite previous supraventricular tachycardia ablation
• Intra-atrial thrombus, tumour, or other abnormality precluding catheter insertion
• Wolff-Parkinson-White syndrome
• Heart failure with New York Heart Association (NYHA) class III or IV or ejection
fraction ≤ 35%
• Unstable angina or acute myocardial infarction within 3 months
• Cardiac revascularisation or other cardiac surgery within 6 months or with prior
atrial surgery
• Renal failure requiring dialysis, or hepatic failure
• An implanted device (pacemaker or cardioverter-defibrillator)
• Left atrial diameter > 60 mm
Randomised: Control: 19, Intervention: 26
Age (mean in years): Control: 62.3, Intervention: 62.2
%Male gender: Control: 64, Intervention: 54
Interventions Control: The antiarrhythmic drug preferentially administered was amiodarone. In par-
ticipants with history of intolerance to amiodarone, a class IC antiarrhythmic was ad-
ministered. The final decision was left to the physician
Intervention: Pulmonary vein isolation, circumferential ablation, plus left atrial linear
lesion ± cavo-tricuspid isthmus
Outcomes Analysis was by intention-to-treat
Primary outcomes
1. Absence of any recurrence of atrial arrhythmias
Control: 6/69, Intervention: 38/68
2. % Needing cardioversion after blanking period
Control: 0/69, Intervention: 0/77
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Stabile 2006 (Continued)
Notes Only participants that had persistent AF were included in the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated.
Allocation concealment (selection bias) Unclear risk Method for allocation concealment not specified by authors.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants receiving ablation due to the
nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up.
Selective reporting (reporting bias) Low risk No evidence of selective reporting. Pre-specified outcomes were
reported
Other bias Unclear risk Our analysis is restricted to the subsample of participants with
persistent AF
ADT: antiarrhythmic drug treatment
AF: atrial fibrillation
CA: cardiac ablation
ECG: electrocardiogram
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Andrade 2014 Mixed population with > 75% paroxysmal atrial fibrillation.
Bladino 2013 Not RCT.
Cosedis 2012 Not addressing prespecified population; participants with paroxysmal atrial fibrillation
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(Continued)
Gaita 2008 Not addressing prespecified intervention; study comparing two different ablation strategies
Hunter 2014 Not addressing prespecified comparison; ablation compared to rate control and follow-up not up to 12months
Jais 2008 Not addressing prespecified population; participants with paroxysmal atrial fibrillation
Jones 2013 Not addressing prespecified comparison; study on rate control
Krittayaphong 2003 Mixed population with > 90% paroxysmal atrial fibrillation.
MacDonald 2011 Not addressing prespecified comparison; study on rate control
Morillo 2014 Not addressing prespecified intervention; on participants with paroxysmal atrial fibrillation
Oral 2006 Study did not directly compare antiarrhythmic drug therapy to circumferential pulmonary vein ablation. Also,
77% of the participants in the AAD group crossed over to undergo circumferential pulmonary vein ablation
in addition to antiarrhythmic drug therapy
Packer 2013 Mixed population with > 75% paroxysmal atrial fibrillation.
Pappone 2006 Not addressing prespecified population; participants with paroxysmal atrial fibrillation
Raatikainen 2015 Not addressing prespecified population; participants with paroxysmal atrial fibrillation
Schneider 2015 Not addressing prespecified population; participants with atrial flutter
Tang 2006 Not RCT.
Wazni 2005 Mixed population with > 90% paroxysmal atrial fibrillation.
Wilber 2010 Not addressing prespecified population; participants with paroxysmal atrial fibrillation
AAD: antiarrhythmic drug
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
NCT00821353
Methods RCT
Participants Country: Poland
Eligibility:
• Ages eligible for study: 18 years to 70 years (adult, senior)
• Genders eligible for study: both
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NCT00821353 (Continued)
• Accepts healthy volunteers: no
Inclusion criteria: Participants with hypertrophic cardiomyopathy and paroxysmal or chronic atrial fibrillation
Exclusion criteria:
• Severe heart failure (NYHA IV)
• Left ventricular ejection fraction < 0.30
• Left atrial diameter > 65 mm
• Age > 70 years
• Contraindication to anticoagulation with warfarin
• Presence of a mechanical prosthetic valve
• Presence of left atrial thrombus on TEE or CT
• Woman currently pregnant
• Renal failure (GFR < 30 ml/min)
• Hepatic failure
• Untreated hypothyroidism or hyperthyroidism
• LVOT gradient > 50 mmHg
Estimated enrolment: 90
Follow-up: 12 months
Interventions Control: Antiarrhythmic drugs (preferably amiodarone) and cardioversion in cases of chronic AF
Intervention: Radiofrequency catheter ablation
Outcomes Primary Outcome
1. Freedom from atrial fibrillation and atrial flutter (> 1 min) on or off antiarrhythmic medications
Secondary outcomes
1. Changes in total symptomatic and asymptomatic AF burden
2. Incidence of complications
3. Changes in left atrial diameter and left ventricular function
4. Changes in level of Nt-pro-BNP
5. Changes in symptom severity and quality of life
6. Changes in exercise capacity assessed by cardiopulmonary exercise testing
Notes Please refer to this study by its ClinicalTrials.gov identifier: NCT00821353. Phase three completed but not published
as of when this review was developed
AF: atrial fibrillation
RCT: randomised controlled trial
CT: computerized tomography
GFR: glomular filtration rate
LVOT: left ventricular outflow tract
Nt-pro-BNP: N-terminal pro-brain natriuretic peptide
NYHA: New York Heart Association
RCT: randomised controlled trial
TEE: transesophageal echocardiography
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Characteristics of ongoing studies [ordered by study ID]
NCT00196209
Trial name or title Randomized study comparing cardioversion vs. catheter ablation in patients with persistent atrial fibrillation
Methods RCT
Participants Country: Germany
Eligibility:
• Ages eligible for study: 20 years to 75 years (adult, senior).
• Genders eligible for study: both.
• Accepts healthy volunteers: no.
Inclusion criteria:
• Age > 20 years and < 75 years.
• Documented persistent atrial fibrillation for at least 3 months (documented in at least 2 ECGs or
Holter-ECGs during the previous 3 months before inclusion and persistent atrial fibrillation in a 7-day-
Holter).
• Documented sufficient anticoagulation for at least 4 weeks before inclusion.
Exclusion criteria:
• Paroxysmal atrial fibrillation.
• NYHA IV (if recompensation is not possible).
• Contraindication for warfarin.
• Disturbance of blood coagulation.
• Myocardial infarction, PTCA/stenting, bypass operation, stroke, intracranial bleeding less than 3
months before.
• Reversible causes of atrial fibrillation (i.e. hyperthyroidism).
• Pregnancy.
• LA diameter > 55 mm.
• LV function < 30% EF.
• Aortic or mitral stenosis or regurgitation III°-IV°.
• Prosthetic valves.
Estimated enrolment: 130
Follow-up: 6 months
Interventions Control: Cardioversion and drug prophylaxis to treat persistent atrial fibrillation
Intervention: Catheter ablation to treat persistent atrial fibrillation.
Outcomes Primary outcome: Event-free survival after 6 months (i.e. freedom of atrial tachyarrhythmias - as evaluated
in a 7-day-Holter, stroke, pulmonary vein stenosis - as evaluated in a CT-/MRT scan 6 months after the
initial procedure - and death)
Secondary outcomes:
• Success-rate immediately after intervention.
• Need for reintervention between 2 and 3 months after initial procedure if not stable sinus rhythm at
the two-month follow-up (further ablation/cardioversion).
• Burden of atrial fibrillation in a 7-day-Holter after 6 months.
• Significant improvement in exercise capacity (measured by spiroergometry).
• Decrease in NT-pro-BNP levels in the blood after 6 months compared to the level before initial
intervention.
• Improvement of quality of life (combined questionnaire including the SF-36 form) before initial
intervention and at the 6-months follow-up.
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NCT00196209 (Continued)
Starting date August 2005
Contact information Heidi L Estner, MD; 0049 89 1218 2020; estner@dhm.mhn.de
Notes Please refer to this study by its ClinicalTrials.gov identifier: NCT00196209. The recruitment status of this
study is unknown
NCT00911508
Trial name or title Catheter ablation vs anti-arrhythmic drug therapy for atrial fibrillation trial
Methods RCT
Participants Country: USA
Eligibility:
• Ages eligible for study: 18 years to 90 years (adult, senior).
• Genders eligible for study: both.
• Accepts healthy volunteers: no.
Inclusion criteria:
Over the preceding 6 months have:
• ≥ 2 paroxysmal (electrocardiographic documentation of at least 1) AF episodes lasting ≥ 1 hour in
duration: (that terminate spontaneously within 7 days or cardioversion is performed within 48 hours of AF
onset): or
• electrocardiographic documentation of 1 persistent AF episode: (sustained for ≥ 7 days or
cardioversion is performed more than 48 hours after AF onset): or
• electrocardiographic documentation of 1 longstanding persistent AF episode: (continuous AF of
duration > 1 year).
• Warrant active therapy (within the past 3 months) beyond simple ongoing observation.
• Be eligible for catheter ablation and ≥ 2 sequential rhythm control and/or ≥ 2 rate control drugs.
• Be ≥ 65 yrs of age, or < 65 yrs with one or more of the following risk factors for stroke:
◦ hypertension (treated and/or defined as a blood pressure > 140/90 mmHg)
◦ diabetes (treated and/or defined as a fasting glucose ≥ 126 mg/dl)
◦ congestive heart failure (including systolic or diastolic heart failure)
◦ prior stroke, TIA or systemic emboli
◦ atherosclerotic vascular disease (previous MI, peripheral arterial disease or aortic plaque), LA size
> 5.0 cm (or volume index ≥ 40 cc/m2), or EF ≤ 35.
• Have the capacity to understand and sign an informed consent form.
• Be ≥18 years of age.
• Participants < 65 yrs of age whose only risk factor is hypertension must have a second risk factor or LV
hypertrophy to qualify. Participants receiving new drug therapy initiated within the previous 3 months may
continue that therapy if randomised to the drug therapy arm. Participants may have documented atrial
flutter in addition to atrial fibrillation and remain eligible for enrolment.
Exclusion criteria:
• Lone AF in the absence of risk factors for stroke in participants < 65 years of age.
• Participants who in the opinion of the managing clinician should not yet receive any therapy for AF.
• Participants who have not responded to > 2 membrane active AADs at a therapeutic dose due to
inefficacy or side effects (Table 5.2.2).
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NCT00911508 (Continued)
• An efficacy failure of full dose amiodarone treatment > 8 weeks duration at any time.
• Reversible causes of AF including thyroid disorders, acute alcohol intoxication, recent major surgical
procedures, or trauma.
• Recent cardiac events including MI, PCI, or valve or bypass surgery in the preceding 3 months.
• Hypertrophic obstructive cardiomyopathy (outflow track).
• Class IV angina or Class IV CHF (including past or planned heart transplantation).
• Other arrhythmias mandating AAD therapy (i.e. ventricular tachycardia, ventricular fibrillation).
• Heritable arrhythmias or increased risk for torsade de pointes with class I or III drugs.
• Prior LA catheter ablation with the intention of treating AF.
• Prior surgical interventions for AF such as the MAZE procedure.
• Prior AV nodal ablation.
• Participants with other arrhythmias requiring ablative therapy.
• Contraindication to appropriate anticoagulation therapy.
• Renal failure requiring dialysis.
• Medical conditions limiting expected survival to < 1 year.
• Women of childbearing potential (unless postmenopausal or surgically sterile).
• Participation in any other clinical mortality trial (participation in other non-mortality trials should be
reviewed with the clinical trial management centre).
• Unable to give informed consent.
Estimated enrolment: 2204
Follow-up: until date of event
Interventions Control:Current state-of-the-art drug therapy for atrial fibrillation (rate control or rhythm control). Treating
physicians will be encouraged to follow the American College of Cardiology/American Heart Association/
European Society of Cardiology Atrial Fibrillation Guidelines with regard to drug therapy for atrial fibrillation
Intervention: Pulmonary vein isolation using a circumferential ablative approach in the left atrium. Ablation
may be performed using circular mapping catheter-guided ablation, antral isolation using a circular guided
approach, or wide area circumferential ablation
Outcomes Primary outcome: LA catheter ablation is superior to rate or rhythm control drug therapy for decreasing the
incidence of the composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest in
participants warranting therapy for AF
Secondary outcomes: LA catheter ablation is superior to rate or rhythm control drug therapy for reducing
total mortality
• Total mortality or cardiovascular hospitalisation.
• Cardiovascular death.
• Cardiovascular death or disabling stroke.
• Arrhythmic death or cardiac arrest.
• Heart failure death.
• Freedom from recurrent AF.
• Cardiovascular hospitalisation.
• Medical costs, resource utilisation, and cost-effectiveness.
• Quality of life.
• Composite adverse events.
• Left atrial size, morphology and function and its relationship to morbidity and mortality.
Starting date August 2009
Contact information Douglas L Packer, MD, Mayo Clinic
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NCT00911508 (Continued)
Notes Please refer to this study by its ClinicalTrials.gov identifier: NCT00911508. This study is ongoing, but not
recruiting participants
NCT01420393
Trial name or title A randomized ablation-based atrial fibrillation rhythm control versus rate control trial in patients with heart
failure and high burden atrial fibrillation
Methods RCT
Participants Country: Canada
Eligibility:
• Ages eligible for study: 18 years and older (adult, senior).
• Genders eligible for study: both.
• Accepts healthy volunteers: no.
Inclusion criteria:
Participants with one of the following AF categories and at least one ECG documentation of AF
• High burden paroxysmal defined as ≥ 4 episodes of AF in the last 6 months, and at least one episode >
6 hours (and no episode requiring cardioversion and no episode > 7 days).
• Persistent AF (1) defined as ≥ 4 episodes of AF in the last 6 months, and at least one episode > 6
hours, and at least one AF episode less than 7 days but requires cardioversion. No AF episodes are > 7 days.
• Persistent AF (2) as defined by at least one episode of AF > 7 days but not > 1 year.
• Long-term persistent AF defined as an AF episode, at least one year in length and no episodes > 3 years.
• Optimal therapy for heart failure of at least 6 weeks (according to 2009 ACCF/AHA class 1
recommendations).
• HF with NYHA class II or III symptoms with either impaired LV function (LVEF ≤ 45%) as
determined by EF assessment within the previous 12 months or preserved LV function (LVEF > 45%)
determined by EF assessment within the previous 12 months.
• NT-pro BNP measures: A) participant has been hospitalised for heart failure (heart failure admission is
defined as admission to hospital > 24 hours and received treatment for heart failure) in the past 9 months,
has been discharged and: i) is presently in normal sinus rhythm and NT-pro BNP is ≥ 400 pg/mL; ii) is
presently in atrial fibrillation and NT-pro BNP is ≥ 600 pg/mL or B) participant has had no hospitalisation
for heart failure in the past 9 months and: i) has had paroxysmal atrial fibrillation, is presently in normal
sinus rhythm and NT-proBNP is ≥ 600 pg/mL; ii) is presently in atrial fibrillation and NT-proBNP is ≥
900 pg/mL.
• Suitable candidate for catheter ablation or rate control therapy for the treatment of AF.
• Age ≥ 18.
Exclusion criteria:
• Have an LA dimension > 55 mm as determined by echocardiography within the previous year.
• Had an acute coronary syndrome or coronary artery bypass surgery within 12 weeks.
• Have rheumatic heart disease, severe aortic or mitral valvular heart disease using the AHA/ACC
guidelines.
• Have congenital heart disease including previous ASD repair, persistent left superior vena cava.
• Had prior surgical or percutaneous AF ablation procedure or atrioventricular nodal (AVN) ablation.
• Have a medical condition likely to limit survival to < 1 year.
• Have New York Heart Association (NYHA) class IV heart failure symptoms.
• Have contraindication to systematic anticoagulation.
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NCT01420393 (Continued)
• Have renal failure requiring dialysis.
• AF due to reversible cause, e.g. hyperthyroid state.
• Are pregnant.
• Are included in other clinical trials that will affect the objectives of this study.
• Have a history of non-compliance to medical therapy.
• Are unable or unwilling to provide informed consent.
Estimated enrolment: 600
Follow-up: 5 years
Interventions Control: Participants in the rate control group will receive optimal heart failure therapy and rate control
measures to achieve a resting HR < 80 beats per minute (bpm) and 6-minute walk HR < 110 bpm
Intervention: Participants randomised to catheter ablation-based AF rhythm control group will receive opti-
mal heart failure therapy and one or more aggressive catheter ablation, which include PV antral ablation and
LA substrate ablation with or without adjunctive antiarrhythmic drug
Outcomes Primary outcome: Composite of all-cause mortality and hospitalisation for heart failure defined as an ad-
mission to a health care facility for > 24 hours
Secondary outcomes:
• All-cause mortality.
• Cardiovascular mortality.
• All-cause hospitalisation.
• Heart failure hospitalisation.
• Cardiovascular hospitalisation.
• Health-related quality of life (MLWHF, EQ5D, AFEQT, Specific Activity scale).
• Health economics.
• 6-minute walk (6MW) distance.
• CCS-SAF scale.
Starting date September 2011
Contact information Anthony Tang, MD; anthonysltang@gmail.com
Notes Please refer to this study by its ClinicalTrials.gov identifier: NCT01420393. This study is currently recruiting
participants
AFEQT: atrial fibrillation effect on quality-of-life
ASD: atrial septal defect
AV: Atrioventricular
CCS-SAF: Canadian cardiovascular society severity of atrial fibrillation
CHF: congestive heart failure
EF: ejection fraction
EQ5D: EuroQol five dimensions
HR: heart rate
HF: heart failure
LA: left atrial
LV: left ventricular
LVEF: left ventricular ejection fraction
MI: myocardial infarction
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MLWHF: Minnesota living with heart failure
MRT: magnetic resonance tomography
Nt-pro-BNP: N-terminal pro-brain natriuretic peptide
PCI: percutaneous coronary intervention
PTCA: percutaneous transluminal coronary angioplasty
PV: pulmonary vein
TIA: transient Ischaemic attack
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D A T A A N D A N A L Y S E S
Comparison 1. Ablation versus antiarrhythmic drugs for non-paroxysmal atrial fibrillation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Freedom from atrial arrhythmia
at 12 months follow-up
(random-effects model)
3 261 Risk Ratio (M-H, Random, 95% CI) 1.84 [1.17, 2.88]
2 Freedom from atrial arrhythmia
at 12 months follow-up
(fixed-effect model)
3 261 Risk Ratio (M-H, Fixed, 95% CI) 1.94 [1.48, 2.55]
3 Participants needing
cardioversion
3 261 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.47, 0.82]
4 Cardiac hospitalisation 2 216 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.10, 0.72]
5 Significant bradycardia or need
for a pacemaker
3 261 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.02, 1.63]
6 Periprocedural complications
and other safety outcomes
(random-effects model)
3 261 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.16, 5.68]
7 Periprocedural complications
and other safety outcomes
(fixed-effect model)
3 261 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.33, 2.21]
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Analysis 1.1. Comparison 1 Ablation versus antiarrhythmic drugs for non-paroxysmal atrial fibrillation,
Outcome 1 Freedom from atrial arrhythmia at 12 months follow-up (random-effects model).
Review: Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation
Comparison: 1 Ablation versus antiarrhythmic drugs for non-paroxysmal atrial fibrillation
Outcome: 1 Freedom from atrial arrhythmia at 12 months follow-up (random-effects model)
Study or subgroup Ablation AADs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Forleo 2009 28/35 15/35 45.5 % 1.87 [ 1.23, 2.83 ]
Mont 2014 69/98 21/48 51.9 % 1.61 [ 1.14, 2.27 ]
Stabile 2006 13/26 0/19 2.6 % 20.00 [ 1.26, 316.89 ]
Total (95% CI) 159 102 100.0 % 1.84 [ 1.17, 2.88 ]
Total events: 110 (Ablation), 36 (AADs)
Heterogeneity: Tau2 = 0.07; Chi2 = 3.89, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 2.65 (P = 0.0080)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours AADs Favours Ablation
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Analysis 1.2. Comparison 1 Ablation versus antiarrhythmic drugs for non-paroxysmal atrial fibrillation,
Outcome 2 Freedom from atrial arrhythmia at 12 months follow-up (fixed-effect model).
Review: Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation
Comparison: 1 Ablation versus antiarrhythmic drugs for non-paroxysmal atrial fibrillation
Outcome: 2 Freedom from atrial arrhythmia at 12 months follow-up (fixed-effect model)
Study or subgroup Ablation AADs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Forleo 2009 28/35 15/35 34.3 % 1.87 [ 1.23, 2.83 ]
Mont 2014 69/98 21/48 64.4 % 1.61 [ 1.14, 2.27 ]
Stabile 2006 13/26 0/19 1.3 % 20.00 [ 1.26, 316.89 ]
Total (95% CI) 159 102 100.0 % 1.94 [ 1.48, 2.55 ]
Total events: 110 (Ablation), 36 (AADs)
Heterogeneity: Chi2 = 3.89, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 4.76 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours AADs Favours Ablation
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Analysis 1.3. Comparison 1 Ablation versus antiarrhythmic drugs for non-paroxysmal atrial fibrillation,
Outcome 3 Participants needing cardioversion.
Review: Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation
Comparison: 1 Ablation versus antiarrhythmic drugs for non-paroxysmal atrial fibrillation
Outcome: 3 Participants needing cardioversion
Study or subgroup Ablation AADs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Forleo 2009 0/35 0/35 Not estimable
Mont 2014 34/98 24/48 59.0 % 0.69 [ 0.47, 1.03 ]
Stabile 2006 13/26 19/19 41.0 % 0.51 [ 0.35, 0.75 ]
Total (95% CI) 159 102 100.0 % 0.62 [ 0.47, 0.82 ]
Total events: 47 (Ablation), 43 (AADs)
Heterogeneity: Chi2 = 1.25, df = 1 (P = 0.26); I2 =20%
Test for overall effect: Z = 3.31 (P = 0.00094)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Ablation Favours AADs
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Analysis 1.4. Comparison 1 Ablation versus antiarrhythmic drugs for non-paroxysmal atrial fibrillation,
Outcome 4 Cardiac hospitalisation.
Review: Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation
Comparison: 1 Ablation versus antiarrhythmic drugs for non-paroxysmal atrial fibrillation
Outcome: 4 Cardiac hospitalisation
Study or subgroup Ablation AADs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Forleo 2009 3/35 12/35 74.9 % 0.25 [ 0.08, 0.81 ]
Mont 2014 2/98 3/48 25.1 % 0.33 [ 0.06, 1.89 ]
Total (95% CI) 133 83 100.0 % 0.27 [ 0.10, 0.72 ]
Total events: 5 (Ablation), 15 (AADs)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.63 (P = 0.0085)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Ablation Favours AADs
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Analysis 1.5. Comparison 1 Ablation versus antiarrhythmic drugs for non-paroxysmal atrial fibrillation,
Outcome 5 Significant bradycardia or need for a pacemaker.
Review: Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation
Comparison: 1 Ablation versus antiarrhythmic drugs for non-paroxysmal atrial fibrillation
Outcome: 5 Significant bradycardia or need for a pacemaker
Study or subgroup Ablation AADs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Forleo 2009 1/35 5/35 100.0 % 0.20 [ 0.02, 1.63 ]
Mont 2014 0/98 0/48 Not estimable
Stabile 2006 0/26 0/19 Not estimable
Total (95% CI) 159 102 100.0 % 0.20 [ 0.02, 1.63 ]
Total events: 1 (Ablation), 5 (AADs)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Ablation Favours AADs
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Analysis 1.6. Comparison 1 Ablation versus antiarrhythmic drugs for non-paroxysmal atrial fibrillation,
Outcome 6 Periprocedural complications and other safety outcomes (random-effects model).
Review: Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation
Comparison: 1 Ablation versus antiarrhythmic drugs for non-paroxysmal atrial fibrillation
Outcome: 6 Periprocedural complications and other safety outcomes (random-effects model)
Study or subgroup Ablation AADs Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Forleo 2009 1/35 6/35 34.1 % 0.17 [ 0.02, 1.31 ]
Mont 2014 6/98 2/48 42.2 % 1.47 [ 0.31, 7.01 ]
Stabile 2006 3/26 0/19 23.6 % 5.19 [ 0.28, 94.82 ]
Total (95% CI) 159 102 100.0 % 0.94 [ 0.16, 5.68 ]
Total events: 10 (Ablation), 8 (AADs)
Heterogeneity: Tau2 = 1.35; Chi2 = 4.35, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Ablation Favours AADs
42Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.7. Comparison 1 Ablation versus antiarrhythmic drugs for non-paroxysmal atrial fibrillation,
Outcome 7 Periprocedural complications and other safety outcomes (fixed-effect model).
Review: Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation
Comparison: 1 Ablation versus antiarrhythmic drugs for non-paroxysmal atrial fibrillation
Outcome: 7 Periprocedural complications and other safety outcomes (fixed-effect model)
Study or subgroup Ablation AADs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Forleo 2009 1/35 6/35 64.8 % 0.17 [ 0.02, 1.31 ]
Mont 2014 6/98 2/48 29.0 % 1.47 [ 0.31, 7.01 ]
Stabile 2006 3/26 0/19 6.2 % 5.19 [ 0.28, 94.82 ]
Total (95% CI) 159 102 100.0 % 0.86 [ 0.33, 2.21 ]
Total events: 10 (Ablation), 8 (AADs)
Heterogeneity: Chi2 = 4.35, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Ablation Favours AADs
A D D I T I O N A L T A B L E S
Table 1. Further details of included studies
Study Name Forleo 2009 Mont 2014 Stabile 20061
Study period January 2005-September 2006 May 2009-November 2011 February 2002-June 2003
No. participants per arm
(Intervention/comparator)
35 / 35 98 / 48 26 / 19
Average follow-up (months) 12 12 18
No. participants
lost-to-follow up
(intervention/comparator)
0 / 0 3 / 0 This information was not avail-
able for the sub-group with per-
sistent AF
% participants with paroxys-
mal atrial fibrillation
(intervention/comparator)
37 / 46 0 / 0 0 / 0
Though the original trial in-
cluded paroxysmal atrial fibril-
lation, this reported only anal-
ysed persistent atrial fibrillation
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Table 1. Further details of included studies (Continued)
Interventions postrandomisa-
tion and before Ablation
AADs were not suspended be-
fore the ablation.
AAD were discontinued ≥5
half-life periods (or≥1week for
amiodarone) before ablation
Not described.
Type of ablation
(Surgical vs radiofrequency
catheter)
Radiofrequency Catheter Radiofrequency Catheter Radiofrequency Catheter
Ablation technique Pulmonary vein isolation, seg-
mental ostial + left atrial lin-
ear lesion (roof line, mitral isth-
mus) + CFAE ablation
Pulmonary vein isolation, cir-
cumferential ablation ± cavo-
tricuspid isthmus ± left atrial
linear lesion ± CFAE ablation
Pulmonary vein isolation, cir-
cumferential ablation, plus left
atrial linear lesion ± cavo-tricus-
pid isthmus
Use of AADs posterior to ab-
lation
Participants were discharged on
AAD.
Discontinuation of AADs was
complete within 1 month in
participants without structural
heart disease and up to 3
months in the remainingpartic-
ipants
AADs for 3 months (blanking
period)
AADs were given for the
whole duration of the study.
Participants were preferentially
on amiodarone. In participants
with history of intolerance to
amiodarone, a class IC an-
tiarrhythmic was administered.
The final decisionwas left to the
physician
Comparator arm ADT at maximum tolerable
dose either as single or combi-
nation. The recommended reg-
imen was:
oral flecainide 100 mg e/12
hours, oral propafenone (150-
300 mg) 3 times daily, oral so-
talol at an initial dose of 80
mg three times daily, and oral
amiodarone 600 mg/day for 2
weeks, 400 mg/day for the next
2 weeks, and 200 mg daily
thereafter
In participants with persistent
atrial fibrillation, cardioversion
was performed under a new
ADT to maintain the sinus
rhythm
Discontinuation of the AADs
was not required before inclu-
sion in the ADT group
Participants were treated de-
pending on physician’s choice
and according to current guide-
lines
There was not predefined pro-
tocol on the use of ADT during
the blanking period
The antiarrhythmic drug pref-
erentially ad-
ministered was amiodarone. In
participants with history of in-
tolerance to amiodarone, a class
IC antiarrhythmic was admin-
istered
The final decisionwas left to the
physician.
AAD: antiarrhythmic drugs; ADT: antiarrhythmic drug therapy; CFAE: complex fractionated atrial electrograms
1 Stabile 2006: only participants with persistent atrial fibrillation were included in the analysis.
44Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Characteristics of participants included in the studies
Study Name Forleo 2009 Mont 2014 Stabile 2006
Mean Age (years)
(intervention/comparison)
63.2 / 64.8 55 / 55 62.2 / 62.3
% of women 38.6 22.6 40.9
Selection criteria atrial fibri-
lation-related
Symptomatic paroxysmal or
persistent atrial fibrillation for
≥6 months
Symptomatic persistent atrial
fibrillation: >7 or <7 days re-
quiring electrical or pharma-
cological cardioversion. Partic-
ipants with long-standing per-
sistent atrial fibrillationwere ex-
cluded
Persistent atrial fibrillation: oc-
currence in the previous 12
months of ≥2 episodes of atrial
fibrillation, each lasting > 7 days
before being terminated, or last-
ing less than 7 days but neces-
sitating early cardioversion. In
all participants, the first diagno-
sis of atrial fibrillation had been
made at least 6 months before
enrolment
History of AADs Participants had to be refractory
to ≥1 class 1-3 AADs.
Participants had to be refractory
to at least one class I or class III
AADs
Participants had to be intoler-
ant to AADs or in whom two or
more AADs regimens had failed
Atrial fibrillation History
(years)
(intervention/comparison)
3.4 / 3 N.R 5.1 / 7.1
Mean LA size (mm)
(intervention/comparison)
44.3 / 45.2 41.3 / 42.7 46 / 45.4
Mean LVEF (%)
(intervention/comparison)
54.6 / 52.6 61.1 / 60.8 59.1 / 57.9
% any CV co-morbidity[1]
(intervention/comparison)
45.7 / 54.3 10 / 8 63.2 / 62.3
% CV co-morbidities: Oral refers to Nonischemic cardiomyopathy, coronary artery disease, valvular heart disease and congenital heart
disease. Forleo refers to structural heart disease (CHD, dilated cardiomyopathy, valve disease and previous embolic episodes). Mont
refers to TIA, Stroke, peripheral embolism and ischaemic cardiomyopathy. Stabile refers to heart disease. NR, not reported
Table 3. Study characteristics regarding the ascertainment of their primary outcome - freedom from atrial arrhythmias
Study name Forleo 2009 Mont 2014 Stabile 2006
Outcome definition Time to the first atrial fibrilla-
tion (or atypical flutter) recur-
rence after 5 weeks and within
Any episode of atrial fibrillation
or flutter lasting > 24 hours or
requiring cardioversion after a
Absence of any recurrence of
atrial arrhythmias (atrial fibril-
lation or flutter) lasting > 30
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Table 3. Study characteristics regarding the ascertainment of their primary outcome - freedom from atrial arrhythmias
(Continued)
12 months after randomisation 3-month blanking period seconds in the 1-year follow-up,
after the 1-month blanking pe-
riod
Censoring Participants were censored after
first atrial fibrillation recurrence
Participants were censored after
first atrial fibrillation recurrence
Participants were censored af-
ter first occurrence of atrial ar-
rhythmias (atrial fibrillation or
flutter)
Definition of atrial arrhyth-
mias (primary outcome)
Electrocardiographically-
confirmed episode of atrial fib-
rillation or atypical flutter had
to last “> 30 seconds”
Atrial fibrillation or flutter last-
ing > 24 hours or requiring car-
dioversion
In cases where the Holter
recorded atrial fibrillation < 24
hours, symptoms were taken
into consideration
Atrial arrhythmias lasting > 30
seconds.
Blanking period 5 weeks. 3 months. 1 month.
Mode of ascertainment Pulse evaluation confirmed by
ECGwhen any arrhythmia was
suspected and Holter monitor-
ing
A 24-hour Holter monitor. Transtelephonic ECG record-
ing (Life watch monitor) and
Holter monitoring
Frequency of ascertainment Pulse: regularly.
Holter: during visits a 1, 3, 6, 9
and 12 months.
Holter: 6 and 12 months. Transtelephonic ECG: daily for
3 months and whenever they
had palpitations
Holter: 1, 4, 7, 10, and 13
months.
ECG: electrocardiogram
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A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL
#1 MeSH descriptor: [Atrial Fibrillation] this term only
#2 (atrial near/3 fibrillat*):ti,ab,kw (Word variations have been searched)
#3 (auricular* near/3 fibrillat*):ti,ab,kw (Word variations have been searched)
#4 (atrium near/3 fibrillat*):ti,ab,kw (Word variations have been searched)
#5 atrial arrhythmi*:ti,ab,kw (Word variations have been searched)
#6 #1 or #2 or #3 or #4 or #5
#7 MeSH descriptor: [Catheter Ablation] this term only
#8 (catheter near/6 (ablat* or isolat*)):ti,ab,kw (Word variations have been searched)
#9 (transcatheter and (ablat* or isolat*)):ti,ab,kw (Word variations have been searched)
#10 ((surgical near/3 ablat*) or MAZE procedure):ti,ab,kw (Word variations have been searched)
#11 #7 or #8 or #9 or #10
#12 #6 and #11
MEDLINE OVID
1. Atrial Fibrillation/
2. (atrial adj3 fibrillat*).tw.
3. (auricular* adj3 fibrillat*).tw.
4. (atrium adj3 fibrillat*).tw.
5. atrial arrhythmi*.tw.
6. or/1-5
7. Catheter Ablation/
8. (catheter adj6 (ablat$ or isolat$)).tw.
9. (transcatheter and (ablat$ or isolat$)).tw.
10. ((surgical adj3 ablat$) or MAZE procedure).tw.
11. or/7-10
12. 6 and 11
13. adverse effects.fs.
14. contraindications.fs.
15. poisoning.fs.
16. toxicity.fs.
17. drug effects.fs.
18. (toxi* adj2 (effect or effects or reaction* or event or events or outcome*)).tw.
19. (adverse* adj2 (effect or effects or reaction* or event or events or outcome*)).tw.
20. (side adj3 (effect or effects)).tw.
21. (adr or adrs).tw.
22. or/13-21
23. exp animals/ not humans.sh.
24. 22 not 23
25. 12 and 24
26. randomized controlled trial.pt.
27. controlled clinical trial.pt.
28. randomized.ab.
29. placebo.ab.
30. drug therapy.fs.
31. randomly.ab.
32. trial.ab.
33. groups.ab.
34. 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33
35. exp animals/ not humans.sh.
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36. 34 not 35
37. 12 and 36
EMBASE OVID
1. heart atrium fibrillation/
2. (atrial adj3 fibrillat*).tw.
3. (auricular* adj3 fibrillat*).tw.
4. (atrium adj3 fibrillat*).tw.
5. atrial arrhythmi*.tw.
6. or/1-5
7. Catheter Ablation/
8. (catheter adj6 (ablat$ or isolat$)).tw.
9. (transcatheter and (ablat$ or isolat$)).tw.
10. ((surgical adj3 ablat$) or MAZE procedure).tw.
11. or/7-10
12. ae.fs.
13. to.fs.
14. co.fs.
15. si.fs.
16. (toxi* adj2 (effect or effects or reaction* or event or events or outcome*)).tw.
17. (adverse* adj2 (effect or effects or reaction* or event or events or outcome*)).tw.
18. (side adj3 (effect or effects)).tw.
19. (adr or adrs).tw.
20. adverse drug reaction/
21. or/12-20
22. (animal/ or nonhuman/) not human/
23. 21 not 22
24. 6 and 11 and 23
25. random$.tw.
26. factorial$.tw.
27. crossover$.tw.
28. cross over$.tw.
29. cross-over$.tw.
30. placebo$.tw.
31. (doubl$ adj blind$).tw.
32. (singl$ adj blind$).tw.
33. assign$.tw.
34. allocat$.tw.
35. volunteer$.tw.
36. crossover procedure/
37. double blind procedure/
38. randomized controlled trial/
39. single blind procedure/
40. 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39
41. (animal/ or nonhuman/) not human/
42. 40 not 41
43. 6 and 11 and 42
44. 24 or 43
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol of the Review, we planned to address the ’percentage of participants needing cardioversion’ as a primary outcome but
addressed ’participants needing cardioversion’ instead; participants needing cardioversion is easier to analyse and interpret.
We planned on searching relevant manufacturers’ websites for trial information but did not do this because we searched other relevant
websites, more suited to our Review questions instead.
We used a random-effects model to incorporate unexplained moderate heterogeneity where the I² statistic was greater than 40%, as
opposed to the I² statistic greater than 50%, as a more accurate conclusion would be drawn by investigating and using a random-effects
model to incorporate an I² statistic greater than 40%.
In the protocol of the Review our objective was to determine the effect of ablation to maintin sinus rhythm in patients with persistent or
long-standing persistent atrial fibrillation compared to anti-arrhythmic drugs. In our Review we havemodified to objective to determine
the efficacy and safety of ablation (catheter and surgical) in people with non-paroxysmal (persistent or long-standing persistent) atrial
fibrillation compared to antiarrhythmic drugs.
In the protocol of the Review we planned to include only randomised controlled trials (RCTs) of parallel-group design with the
individual or cluster as the unit of randomisation. In our Review we included only randomised trials of parallel-group design with the
individual as the unit of randomisation.
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